

Hampshire Medicines Safety Group

How to record Hospital Prescribed Medicines on GP Prescribing Systems

It is important to record all medicines prescribed by the hospital (for which the hospital retain prescribing responsibility) on the GP prescribing system individual patient record.

If this is not possible, target higher risk medicines: A list of these is included in this guide.

Why is this important?

Potential risks of not recording hospital prescribed medicines include:

- inadvertent co-prescribing of interacting medicines,
- the potential to miss side effects or not attribute them to drug therapy
- hospital prescribed medicines will not be recorded on the Summary Care Record
- potential for doses to be missed if a person is admitted to a different hospital provider

How should information be recorded?

This guide provides instructions on how to record this information on GP prescribing systems:

- EMIS
- Vision
- TPP SystemOne

It is not necessary or practical to record accurate details of formulation and dose if the hospital has accepted ongoing prescribing responsibility, because details may change frequently.

Select the nearest match strength and formulation from the pull down menu.

Select the free-text dose option and enter “**dose and formulation managed by xxx hospital**”

It is equally important to remove the details when the hospital informs the Practice that the medicine has been stopped.

EMIS

1. Retrieve the patient record
2. Follow the usual method of adding a medication to a patients record but under **dosage** add text to indicate who issues the medication:
 - a. For Hospital medication add "HOSPITAL ONLY, ONLY TO BE ISSUED BY *CLINIC NAME*"
 - b. For Dental medication add "DENTAL ONLY, ONLY TO BE ISSUED BY *DENTIST NAME*"
 - c. For OTC or other medication add "FOR INFORMATION ONLY, NOT TO BE ISSUED"
3. For **quantity** enter 1 as EMIS will not accept no number or 0
4. If required deal with any safety alerts or other messages which are shown
5. Select **Issue**
6. On Issue window, expand the **Change All** tab at the top of the screen and select:
 - a. Hospital (No print) for hospital medications
 - b. Record for Notes (No print) for dental, OTC or other medication

Click **Approve and Complete** to finish








Vision InPS

Refer to the online training guide "Consultation Manager – Therapy":

Record medicines in the Therapy Add using the picklist under Source of Drug:

- Drugs prescribed by a hospital doctor or consultant
- Drugs prescribed by a doctor at another practice while the patient is registered as a temporary patient at that practice
- Contraception prescribed in a Family Planning clinic not run by the practice
- Contraception prescribed outside the practice should be recorded either through the Therapy Add (Source of Drug: by health carer in another practice); AND in Contraceptive Services – Add by unchecking the In Practice tick box.

TPP SystemOne

| | |
|---|---|
| <ul style="list-style-type: none"> Right-click on the Medication node of the Clinical Tree |  |
| <ul style="list-style-type: none"> Select Record Other Medication |  |
| <ul style="list-style-type: none"> Enter the name of the medication you are recording in the Drug and Appliance window Click Search |  |
| <ul style="list-style-type: none"> Select the particular formulation of the drug you require Click Ok |  |
| <ul style="list-style-type: none"> Choose a Medication Source Enter any information about the dose and quantity that you have |  |
| <ul style="list-style-type: none"> Click Ok |  |
| <ul style="list-style-type: none"> Once saved any medications added following the above will appear in the patients SCR. |  |

List of Medicines designated as 'Red'

| Drug Name | Main Reason | Additional information (Usual Indication: specific risk) | Form & Strength | Brand (if applicable) | BNF Ref |
|------------------|-------------------|---|---|------------------------------------|---------------------------|
| Abatacept | Immunosuppression | Rheumatoid arthritis: | Subcutaneous injection 125mg Intravenous injection 250mg | Orencia | 10.1.3 |
| Abiraterone | Immunosuppression | Prostate cancer: | Tablet 250mg | Zytiga | 8.3.4.2 |
| Acitretin | Contraindications | Psoriasis: teratogenic | Capsule 10mg, 12mg | Neotigason | 13.5.2 |
| Adalimumab | Immunosuppression | Inflammatory bowel disease/rheumatology/psoriasis: | Subcutaneous injection 40mg | Humira | 1.5.3 10.1.3 13.5.3 |
| Afatinib | Side Effects | Lung cancer: dermatological, ophthalmologic, pulmonary toxicity and immunosuppression | Tablet 20mg, 30mg, 40mg,50mg | Giotrif | 8.1.5 |
| Allitretinoin | Contraindications | Hand eczema:teratogenic; hyperlipidaemia | Capsule 10mg, 30mg | Toctino | 13.5.1 |
| Apomorphine | Other | Parkinsons disease: Optimisation of other parkinson's medication | Pen injector 30mg Pre-filled syringe 50mg | APO-go | 4.9.1 |
| Bexarotene | Immunosuppression | Cutaneous T-cell lymphoma: | Capsule 75mg | Targretin | 8.1.5 |
| Bleomycin | Side Effects | Various cancers: pulmonary toxicity including progressive pulmonary fibrosis | Injection | | 8.1.2 |
| Boceprevir | Side Effects | Hepatitis C: prolongs QT interval, severe rash with eosinophilia and systemic symptoms, Stevens Johnson Syndrome | Capsule 200mg | Victrelis | 5.3.3.2 |
| Busulfan | Immunosuppression | Chronic myeloid leukaemia: | Tablet 2mg | Myleran | 8.1.1 |
| Canakinumab | Immunosuppression | Acute gout/cryopyrin-associated periodic syndromes/Muckle-Wells Syndrome/neonatal-onset multisystem inflammatory disorders: | Subcutaneous injection 150mg | Ilaris | 8.2.4 |
| Certolizumab | Immunosuppression | Rheumatoid disorders: | Subcutaneous injection 200mg | Cimzia | 10.1.3 |
| Cetuximab | Side Effects | Various cancers: keratitis and ulcerative keratitis | Intravenous injection 100mg, 500mg | Erbutix | 8.1.5 |
| Clozapine | Side Effects | Treatment-resistant schizophrenia: Agranulocytosis, cardiac toxicity, intestinal obstruction | Tablet 25mg, 100mg | Clozaril | 4.2.1 |
| Cyclophosphamide | Immunosuppression | Rheumatoid arthritis and connective tissue disorders/cancer treatment: | Tablet 50mg Intravenous injection 500mg, 1g,2g | | 8.1.1 |
| Dabrafenib | Side Effects | Metastatic melanoma: prolongs QT interval, electrolyte abnormalities especially magnesium, ophthalmological toxicity, immunosuppression. | Capsule 50mg, 75mg | Tafinlar | 8.1.5 |
| Dasatinib | Immunosuppression | Chronic myeloid leukaemia: pulmonary arterial hypertension | Tablet 20mg, 50mg, 80mg, 100mg, 140mg | Sprycel | 8.1.5 |
| Denosumab | Side Effects | Prevention of skeletal related events associated with metastases from solid tumours: atypical femoral fractures, jaw osteonecrosis, hypocalcaemia | Subcutaneous injection 120mg | Xgeva | 6.6.2 |
| Eltrombopag | Side Effects | Chronic ITP: cataract fomatation, likely teratogenic | Tablet 25mg, 50mg | Revolade | 9.1.4 |
| Enzalutamide | Interactions | Prostate cancer: concurrent use of medicines which lower seizure threshold or prolong QT interval | Capsule 40mg | Xtandi | 8.3.4.2 |
| Erlotinib | Immunosuppression | Lung cancer: Keratitis and ulcerative keratitis. | Tablet 25mg, 100mg, 150mg | Tarceva | 8.1.5 |
| Etanercept | Immunosuppression | Rheumatoid disease,plaque psoriasis: | Subcutaneous injection 25mg, 50mg | Enbrel | 10.1.3 13.5.3 |
| Everolimus | Immunosuppression | Various cancers: pneumonitis. Caution with concomitant drugs that increase risk of bleeding. | Tablets 2.5mg, 5mg, 10mg | Afinitor/ Votubia | 8.1.5 |
| Fingolimod | Side Effects | Multiple Sclerosis: Cardiotoxicity, immunosuppression | Capsule 500 microgram | Gilenya | 8.2.4 |
| Gefitinib | Immunosuppression | Lung cancer: Keratitis and ulcerative keratitis. | Tablet 250mg | Iressa | 8.1.5 |
| Golimumab | Immunosuppression | Rheumatoid disorders/ulcerative colitis: | Injection 50mg, 100mg | Simponi | 10.1.3 |
| Imatinib | Immunosuppression | Various cancers . | Tablet 100mg, 400mg | Glivec | 8.1.5 |
| Infliximab | Immunosuppression | Various indications in inflammatory diseases and cancer: | Intravenous injection 100mg | Remicade/Inflectra/ Remcina | 1.5.3 10.1.3 |
| Interferon alfa | Immunosuppression | Various cancers: | subcutaneous and intravenous injection | Roferon-A | 5.3.3 8.2.4 |
| Interferon beta | Immunosuppression | Multiple Sclerosis: | Subcutaneous injection | Rebif/Avonex/Extavia/ Betaferon | 8.2.4 |
| Ipilimumab | Immunosuppression | Melanoma: | Intravenous injection 50mg | Vervoy | 8.1.5 |
| Isotretinoin | Contraindications | Acne: teratogenic | Capsule 5mg, 10mg, 20mg, 40mg | Roaccutane | 13.6.2 |
| Ivacaftor | Interactions | Cystic Fibrosis: interactions with drugs affected by or having effects on liver enzymes | Tablet 150mg | Kalydeco | 3.7 |
| Lapatinib | Immunosuppression | Breast cancer: respiratory failure (fatal). Caution with drugs that prolong QT interval | Tablet 250mg | Tyverb | 8.1.5 |
| Lenalidomide | Contraindications | Multiple myeloma/myelodysplastic syndromes: teratogenic; increased thromboembolic risk, Stevens-Johnson Syndrome, toxic epidermal necrosis, liver toxicity,pneumonitis. . | Capsule 5mg,10mg,15mg, 25mg | Revlimid | 8.2.4 |
| Lurasidone | Interactions | Schizophrenia: Avoid concomitant use with potent CYP3A4 inducers or drugs that prolong QT interval | Tablet 18.5mg, 37mg, 74mg | Latuda | 4.2.1 |
| Mepacrine | Side Effects | Various unlicensed uses including lupus and giardiasis aplastic anaemia | Tablet (various strengths) | | 5.4.4 |
| Mercaptopurine | Immunosuppression | Leukaemias and inflammatory bowel disease: | Tablet 50mg | | 8.1.3 |
| Methotrexate | Immunosuppression | Various inflammatory & neoplastic diseases: pulmonary and hepatic toxicity | Tablet 2.5mg Injection (various) | | 8.1.3 |
| Metyrapone | Side Effects | Cushings: side effects related to adrenocortical effect | Capsule 250mg | Metopirone | 6.7.3 |
| Mitotane | Side Effects | Adreno-cortical carcinoma: acute adrenal insufficiency, CNS toxicity, immunosuppression | Tablet 500mg | Lysodren | 8.1.5 |
| Mycophenolate | Immunosuppression | Transplant rejection/various autoimmune conditions: | Tablet, capsule 250mg, 500mg | CellCept/Myfortic | 8.2.1 13.5.3 |
| Natalizumab | Side Effects | Multiple Sclerosis: Risk of PML, liver toxicity | Intravenous injection 300mg | Tysabri | 8.2.4 |
| Nilotinib | Side Effects | CML :increased susceptibility to QT interval prologation | Capsule 150mg, 200mg | Tasigna | 8.1.5 |
| Omalizumab | Side Effects | Severe asthma:Churg-Strauss syndrome | Subcutaneous injection 75mg, 150mg | Xolair | 3.4.2 |
| Pazopanib | Side Effects | Renal cell cancer:many side effects and contra-indications | Tablet 200mg, 400mg | Votrient | 8.1.5 |
| Pomalidomide | Contraindications | Multiple myeloma: teratogenic; increased thromboembolic risk,pulmonary toxicity. | Capsule 1mg, 2mg, 3mg, 4mg | Imnovid | |
| Pirfenidone | Side Effects | Idiopathic Pulmonary Fibrosis: increased risk of photosensitivity | Capsule 267mg | Esbriet | 3.11 |
| Procarbazine | Immunosuppression | Hodgkins lymphoma: | capsule 50mg | | 8.1.5 |
| Rituximab | Immunosuppression | Various indications: | Intravenous injection 100mg, 500mg | MabThera | 8.2.3 |
| Ruxolitinib | Immunosuppression | Myelofibrosis/disease related splenomegaly: | Tablets 5mg,10mg,15mg,20mg | Jakavi | 8.1.5 |
| Sildenafil | Side Effects | Primary Pulmonary Arterial Hypertension: ophthalmological toxicity, priapism | Tablet 20mg | Revatio | 2.5.1 |
| Simeprevir | Side Effects | Genotype 1 chronic hepatitis C: Skin reactions | Capsule 150mg | Olysio | 5.3.3.2 |
| Sorafenib | Side Effects | Multiple indications: multiple side effects including immunosupresion | Tablet 200mg | Nexavar | 8.1.5 |
| Telaprevir | Side Effects | Hepatitis C: Skin reactions | Tablet 275mg | Incivo | 5.3.3.2 |
| Telbivudine | Side Effects | Hepatitis B: Muscle effects and peripheral neuropathy | Tablet 600mg | Sebivo | 5.3.3.1 |

List of Medicines designated as 'Red'

| | | | | | |
|-----------------------|--------------------------|--|---|------------------|---------|
| Temozolomide | Immunosuppression | Glioblastoma: | capsule 5mg, 20mg,100mg, 140mg, 180mg,250mg | Temodal | 8.1.5 |
| Temsirolimus | Immunosuppression | Renal cell cancer/mantle cell lymphoma: | Intravenous injection 30mg | Torisel | 8.1.5 |
| Tenofovir | Side Effects | Chronic Hepatitis B/HIV: Nephrogenic diabetes insipidus, renal failure | Tablet 123mg, 163mg, 204mg, 245mg | Viread | 5.3.1 |
| Teriflunomide | Immunosuppression | Multiple Sclerosis: | Tablet 14mg | Aubagio | 8.2.4 |
| Thalidomide | Contraindications | Renal cell carcinoma/multiple myeloma: teratogenic; thromboembolism and blood disorders | Capsule 50mg, tablet 25mg | Talidex | 8.2.4 |
| Tocilizumab | Immunosuppression | Rheumatoid Arthritis: | Intravenous injection 80mg, 200mg, 400mg | RoActemra | 10.1.3 |
| Tolvaptan | Side Effects | SIADH/polycystic kidney disease: hepatic impairment, hypernatraemia | Tablet15mg, 30mg | Samsca | 6.5.2 |
| Trastuzumab | Immunosuppression | Breast cancer | Injection 150mg, 600mg | Herceptin | 8.1.5 |
| Ustekinumab | Immunosuppression | Plaque psoriasis: | Subcutaneous injection 45mg | Stelara | 10.1.3 |
| Valganciclovir | Side Effects | CMV prevention: haematological abnormalities, potential carcinogen and teratogen | Tablet 450mg | Valcyte | 5.3.2.2 |
| Vedolizumab | Immunosuppression | Inflammatory bowel disease | Intravenous injection 300mg | Entyvio | 1.5.3 |
| Vemurafenib | Side Effects | Metastatic melanoms: drug rash with eosinophilia and systemic symptoms(DRESS) | Tablet 240mg | Zelboraf | 8.1.5 |